Silo Pharma Expands Collaboration with Sever Pharma for Novel Ketamine Implant Therapeutic
Friday, August 16, 2024
Silo Pharma, Inc., a developmental-stage biopharmaceutical company specializing in novel drug formulations and delivery systems for traditional and psychedelic therapies, today announced a new agreement with Sever Pharma Solutions. This collaboration focuses on the scale-up extrusion of Silo's SP-26 ketamine-loaded implant therapeutic, aimed at treating fibromyalgia and chronic pain. Sever Pharma Solutions will also continue analytical testing of the ketamine hydrochloride (ketamine HCL) polymer implants using the optimal time-released, dose-controlled formulation previously selected by Silo for ongoing pre-clinical studies.
“Sever Pharma Solutions has been a key partner in our earlier production of ketamine implants and validation of the delivery system through successful assay testing,” said Silo CEO Eric Weisblum. “We are excited to continue this collaboration as we advance further pre-clinical testing of our innovative non-opioid chronic pain therapeutic. This process is expected to bring Silo closer to finalizing the optimal dosage and formulation of SP-26 for use in animal studies.”
If clinically successful, SP-26 may qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.
Source: globenewswire.com
